Keri Lantz

Keri Lantz is Chief Financial Officer at Paragon Therapeutics. She has over 15 years of experience building and leading finance and administrative functions at both public and private biotech companies. Most recently Keri was the Chief Financial Officer at ValenzaBio until it was acquired by ACELYRIN. Prior to ValenzaBio, Keri was Vice President Finance and Corporate Controller at BioXcel Therapeutics, Head of Finance Operations at Alexion Pharmaceuticals and Vice President Finance and Corporate Controller at Achillion Pharmaceuticals, until it was acquired by Alexion. Keri has been responsible for internal and external financial reporting,internal controls, compliance, treasury, tax and FP&A. She has also overseen and managed Human Resources and IT functions. Additionally, Keri has led numerous due diligence, acquisition, and public and private offering activities. Keri is a certified public accountant and has a B.S. in Accounting from Central Connecticut State University.